IMMUNE / DIRECT CATALOG PRICING
Thymosin Alpha-1
Thymosin alpha-1 is an endogenous N-terminally acetylated 28-amino-acid peptide; the sequence-identical synthetic form is called thymalfasin.
- Format
- Lyophilized research vial
- Listed formats
- 2
- Available now
- 0
- Catalog class
- Immune
Choose a listed format
- 5 mgRequest current pricingRequest pricing
- 10 mgRequest current pricingRequest pricing
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
Thymosin alpha-1 is an endogenous N-terminally acetylated 28-amino-acid peptide; the sequence-identical synthetic form is called thymalfasin.
The immune classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Immune
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- Contact for current availability
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
Thymosin alpha-1 is an endogenous N-terminally acetylated 28-amino-acid peptide; the sequence-identical synthetic form is called thymalfasin.
- Research covered
- Researchers studied thymosin alpha-1 in randomized human trials across specific immune-related clinical settings, including severe sepsis and chronic hepatitis B.
- Important limit
- Findings are condition-, formulation-, and protocol-specific, and FDA notes that a catalog or compounded material cannot be presumed equivalent to a characterized thymalfasin product.
FACTUAL FAQ
Thymosin Alpha-1 catalog questions
What formats are currently listed?
5 mg, 10 mg. Current price and stock state appear above.
What did researchers study?
Researchers studied thymosin alpha-1 in randomized human trials across specific immune-related clinical settings, including severe sepsis and chronic hepatitis B.
What is the most important evidence limit?
Findings are condition-, formulation-, and protocol-specific, and FDA notes that a catalog or compounded material cannot be presumed equivalent to a characterized thymalfasin product.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →